person · Reporting owner

Strobeck Matthew

Disclosed activity across 5 companies

Tapewire entity: 42321
SEC CIK: 0001377832

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Accelerate Diagnostics, IncAXDX · Entity 78156	Director	January 23, 2024	January 25, 2024
BIODESIX INCBDSX · Entity 6053	Director	January 02, 2026	January 06, 2026
ELUTIA INC.ELUT · Entity 7342	10% owner in previous filing	March 23, 2023	February 20, 2024
QuidelOrtho CorpQDEL · Entity 4986	Director	May 29, 2026	June 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Accelerate Diagnostics, Inc

Report date January 23, 2024 · Filed January 25, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Birchview Fund, LLC	120,682	Reported balance After 2024-01-23 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-01-23 · Purchase · Acquired 100,000 · Balance 120,682 F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common Stock Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2029-01-23	IndirectBy Birchview Fund, LLC	100,000	Reported balance After 2024-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-23 · Purchase · Acquired 100,000 · Balance 100,000 F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	Direct	202,556	Reported balance Holding disclosure · report date 2024-01-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 202,556
Common StockSEC Table I · non-derivative	IndirectAs UGMA Custodian for minor children	2,000	Reported balance Holding disclosure · report date 2024-01-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 2,000

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.

F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

BIODESIX INC

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	6,804	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 6,804 · Balance 6,804 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01	Direct	6,354	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.

F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

ELUTIA INC.

Report date March 23, 2023 · Filed February 20, 2024 · Amendment

Jointly reported with Birchview Capital, LP, Birchview Fund LLC

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,615,184	Reported balance After 2023-03-23 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2023-03-23 · Purchase · Acquired 100,000 · Balance 1,615,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,625,184	Reported balance After 2023-03-23 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2023-03-23 · Purchase · Acquired 10,000 · Balance 1,625,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,643,184	Reported balance After 2023-03-24 transaction · row 3 Amendment: may correct only part of an earlier disclosure. 1 source row Row 3 · 2023-03-24 · Purchase · Acquired 18,000 · Balance 1,643,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,645,184	Reported balance After 2023-03-24 transaction · row 4 Amendment: may correct only part of an earlier disclosure. 1 source row Row 4 · 2023-03-24 · Purchase · Acquired 2,000 · Balance 1,645,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,655,184	Reported balance After 2023-03-27 transaction · row 5 Amendment: may correct only part of an earlier disclosure. 1 source row Row 5 · 2023-03-27 · Purchase · Acquired 10,000 · Balance 1,655,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F4: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above.

Filing footnotes · ownership attribution and instrument terms

F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund.

F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.

F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").

F4: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above.

QuidelOrtho Corp

Report date May 29, 2026 · Filed June 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	34,604	Reported balance After 2026-05-29 transaction · row 1 1 source row Row 1 · 2026-05-29 · Grant · Acquired 6,829 · Balance 34,604 F1: Reflects release of restricted stock units that were previously reported on a Form 4.
Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-29 · Exercise / conversion · Disposed 6,829 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5: The restricted stock units vested on May 29, 2026.
Common StockSEC Table I · non-derivative	IndirectUGMA Account	16,630	Reported balance Holding disclosure · report date 2026-05-29 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 16,630 F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBirchview	38,145	Reported balance Holding disclosure · report date 2026-05-29 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 38,145 F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Managing Partner of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects release of restricted stock units that were previously reported on a Form 4.

F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Managing Partner of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

F5: The restricted stock units vested on May 29, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

QUIDEL CORP /DE/

Report date May 27, 2022 · Filed June 01, 2022

Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-27 transaction · row 1 1 source row Row 1 · 2022-05-27 · Disposition to issuer · Disposed 6,533 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
Common StockSEC Table I · non-derivative	IndirectUGMA Account	Reported balance After 2022-05-27 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-05-27 · Disposition to issuer · Disposed 16,630 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBirchview	Reported balance After 2022-05-27 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-05-27 · Disposition to issuer · Disposed 38,145 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $53.27 · Expires 2028-04-04	Direct	Reported balance After 2022-05-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-05-27 · Disposition to issuer · Disposed 259 · Balance 0 F4: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5: Vested in full.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-27 · Disposition to issuer · Disposed 875 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-27 · Disposition to issuer · Disposed 262 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-05-27 · Disposition to issuer · Disposed 427 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-05-27 · Disposition to issuer · Disposed 85 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.

F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).

F5: Vested in full.

F6: Each restricted stock unit represents the right to receive one share of Quidel common stock.

F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).

F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 18, 2020 Filed Mar 20, 2020 12:31 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock	10,000	$7.11	$71,100.00	Disclosure SEC source: 0001628280-20-003862 · wf-form4_158472188174024.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Birchview Fund, LLC Disclosed balance after: 148,235 F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 15, 2019 Filed May 16, 2019 19:27 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionCommon Stock	1,661	$0.00	$0.00	Disclosure SEC source: 0001209191-19-030634 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. F2 · balance_after: In addition to these shares, the reporting person has sole voting and dispositive power with respect to 30,445 shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · balance_after: In addition to these shares, the reporting person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the reporting person's children. The reporting person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 14, 2019 Filed May 16, 2019 19:27 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Equity Grant) · Derivative	2,100	$0.00	$0.00	Disclosure SEC source: 0001209191-19-030634 · doc4.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F7 · derivative.exercise_date: The restricted stock units vest on May 14, 2020. F7 · derivative.expiration_date: The restricted stock units vest on May 14, 2020. Read SEC document
May 14, 2019 Filed May 16, 2019 19:27 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Premium) · Derivative	262	$0.00	$0.00	Disclosure SEC source: 0001209191-19-030634 · doc4.xml · derivative · entry 3 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262 Underlying: Common Stock · 262 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F5 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F7 · derivative.exercise_date: The restricted stock units vest on May 14, 2020. F5 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F7 · derivative.expiration_date: The restricted stock units vest on May 14, 2020. Read SEC document
May 14, 2019 Filed May 16, 2019 19:27 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Converted) · Derivative	875	$0.00	$0.00	Disclosure SEC source: 0001209191-19-030634 · doc4.xml · derivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 Underlying: Common Stock · 875 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F5 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F6 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 14, 2019. F5 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F6 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 14, 2019. Read SEC document
April 01, 2019 Filed Mar 27, 2020 21:08 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantStock Option (right to buy) · Derivative	12,290	$0.00 Strike: $21.02	$0.00	Disclosure SEC source: 0001628280-20-004265 · wf-form4_158535767340662.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,290 Underlying: Common Stock · 12,290 shares Expires 2029-04-01 F1 · date: This Form 4 was inadvertently not filed within the required time following the transaction date of April 1, 2019. F2 · derivative.exercise_date: The option vests in twelve equal monthly installments, with the first installment vesting on May 1, 2019. Read SEC document
May 16, 2018 Filed May 17, 2018 20:15 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionCommon Stock	108	$0.00	$0.00	Disclosure SEC source: 0001209191-18-031231 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects vesting of prior restricted stock units, which were previously reported on a Form 4. F2 · balance_after: In addition to the these shares, the reporting person has sole voting and dispositive power with respect to 30,445 shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · balance_after: In addition to the these shares, the reporting person is custodian under the Uniform Gift to Minor Act for 13,100 shares held by four of the reporting person's children. The reporting person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 15, 2018 Filed May 17, 2018 20:15 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Equity Grant) · Derivative	1,661	$0.00	$0.00	Disclosure SEC source: 0001209191-18-031231 · doc4.xml · derivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661 Underlying: Common Stock · 1,661 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common Stock. F5 · derivative.exercise_date: The restricted stock units vest on May 15, 2019. F5 · derivative.expiration_date: The restricted stock units vest on May 15, 2019. Read SEC document
April 04, 2018 Filed Apr 6, 2018 19:33 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantNon-Qualified Stock Options · Derivative	259	$0.00 Strike: $53.03	$0.00	Disclosure SEC source: 0001209191-18-024260 · doc4.xml · derivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259 Underlying: Common Stock · 259 shares Expires 2028-04-04 Read SEC document
April 04, 2018 Filed Apr 6, 2018 19:33 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Equity Grant) · Derivative	108	$0.00	$0.00	Disclosure SEC source: 0001209191-18-024260 · doc4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108 Underlying: Common Stock · 108 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 16, 2018. F2 · derivative.expiration_date: The restricted stock units vest on May 16, 2018. Read SEC document
April 01, 2018 Filed Apr 3, 2018 16:05 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantStock Option (right to buy) · Derivative	9,476	$0.00 Strike: $22.85	$0.00	Disclosure SEC source: 0001144204-18-018940 · tv490263_4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,476 Underlying: Common Stock · 9,476 shares Expires 2028-04-01 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments, with the first installment vesting on May 1, 2018. Read SEC document
April 01, 2017 Filed Apr 4, 2017 19:08 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantStock Option (right to buy) · Derivative	11,721	$0.00 Strike: $24.20	$0.00	Disclosure SEC source: 0001144204-17-018993 · v463575_4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,721 Underlying: Common Stock · 11,721 shares Expires 2027-04-01 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments, with the first installment vesting on May 1, 2017. F2 · balance_after: The total number of stock options held by the reporting person was previously aggregated in Table II of the reporting person's previous Form 4s. The number of stock options reported on this Form 4 reflects only the number of stock options of the class reported herein. Read SEC document
January 09, 2017 Filed Jan 10, 2017 19:30 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	PurchaseCommon Stock	8,000	$19.00	$152,000.00	Disclosure SEC source: 0001144204-17-001695 · v456703_4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Through Birchview Fund, LLC Disclosed balance after: 138,235 F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.